Evidence map›Paper›PMID 32970633›Full record

ArticleThe Journal of clinical investigation2021

Tobacco smoking induces metabolic reprogramming of renal cell carcinoma.

James Reigle, Dina Secic, Jacek Biesiada, Collin Wetzel, Behrouz Shamsaei, Johnson Chu, Yuanwei Zang, Xiang Zhang, Nicholas J Talbot, Megan E Bischoff and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cigarette Smoking-RegulatedEnvironment & health (Washington, D.C.) · 2026
    Article
  9. Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

James ReigleDepartment of Cancer Biology and.
Dina SecicDepartment of Cancer Biology and.
Jacek BiesiadaDivision of Biostatistics and Bioinformatics, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Collin WetzelDepartment of Cancer Biology and.
Behrouz ShamsaeiDivision of Biostatistics and Bioinformatics, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Johnson ChuDepartment of Cancer Biology and.
Yuanwei ZangDepartment of Cancer Biology and.
Xiang ZhangDivision of Environmental Genetics and Molecular Toxicology, Department of Environmental and Public Health Sciences, and.
Nicholas J TalbotDepartment of Cancer Biology and.
Megan E BischoffDepartment of Cancer Biology and.
Yongzhen ZhangDepartment of Cancer Biology and.
Charuhas V ThakarDivision of Nephrology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Krishnanath GaitondeDivision of Nephrology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abhinav SidanaDivision of Urology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Hai BuiCincinnati Veteran Affairs Medical Center, Department of Veterans Affairs, Cincinnati, Ohio, USA.
John T CunninghamDepartment of Cancer Biology and.
Qing ZhangDepartment of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC-Chapel Hill, North Carolina, USA.
Laura S SchmidtUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Mario MedvedovicDepartment of Biomedical Informatics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
David R PlasDepartment of Cancer Biology and.
Julio A Landero FigueroaAgilent Metallomics Center of the Americas, Department of Chemistry, University of Cincinnati College of Arts and Science, Cincinnati, Ohio, USA.
Jarek MellerDepartment of Biomedical Informatics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Maria F Czyzyk-KrzeskaDepartment of Cancer Biology and.
University of Cincinnati Medical Center · USVeterans Health Administration · USCincinnati Children's Hospital Medical Center · USQilu Hospital of Shandong University · CNFrederick National Laboratory for Cancer Research · USNational Cancer Institute · USSociety of Environmental Toxicology and Chemistry · USUniversity of North Carolina Health Care · US

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI YADAV, JAGJIT S · 1992 to 2022
$35.4M
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
The Molecular Determinants of Virus Induced Biliary AtresiaR01DK091566 · NIDDK · STANFORD UNIVERSITY · PI GREGORY M TIAO · 2011 to 2026
$4.9M
Role of ubiquitylation in renal cancerR01CA122346 · NCI · UNIVERSITY OF CINCINNATI · PI CZYZYK-KRZESKA, MARIA F · 2007 to 2017
$3.0M
Defining the biological roles of PRPS isozymes in normal and diseased settingsR35GM133561 · NIGMS · UNIVERSITY OF CINCINNATI · PI CUNNINGHAM, TOM · 2019 to 2023
$2.1M
Metabolic Adaptive Responses in CancerR01CA168815 · NCI · UNIVERSITY OF CINCINNATI · PI PLAS, DAVID R · 2013 to 2017
$2.1M
Post-Graduate Hematology/Oncology Translational (PG-HOT) Training ProgramT32CA236764 · NCI · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG, SCAGLIONI, PIER PAOLO · 2019 to 2023
$2.1M
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancerR01CA211732 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, QING · 2017 to 2021
$2.1M
Cell-specific analysis of sub-kinomes in schizophreniaR01MH107487 · NIMH · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MCCULLUMSMITH, ROBERT E, MELLER, JAREK · 2016 to 2020
$1.9M
BLRD VA I01 BX001110NCI NIH HHS R01 CA122346NCI NIH HHS R01 CA168815NCI NIH HHS R01 CA211732NCI NIH HHS R01 CA230904NCI NIH HHS T32 CA117846NCI NIH HHS T32 CA236764NIDDK NIH HHS R01 DK091566NIEHS NIH HHS P30 ES006096NIGMS NIH HHS R01 GM128216NIGMS NIH HHS R35 GM133561NIMH NIH HHS R01 MH107487
6 · The paper itself

Abstract

BACKGROUNDClear cell renal cell carcinoma (ccRCC) is the most common histologically defined renal cancer. However, it is not a uniform disease and includes several genetic subtypes with different prognoses. ccRCC is also characterized by distinctive metabolic reprogramming. Tobacco smoking (TS) is an established risk factor for ccRCC, with unknown effects on tumor pathobiology.METHODSWe investigated the landscape of ccRCCs and paired normal kidney tissues using integrated transcriptomic, metabolomic, and metallomic approaches in a cohort of white males who were long-term current smokers (LTS) or were never smokers (NS).RESULTSAll 3 Omics domains consistently identified a distinct metabolic subtype of ccRCCs in LTS, characterized by activation of oxidative phosphorylation (OXPHOS) coupled with reprogramming of the malate-aspartate shuttle and metabolism of aspartate, glutamate, glutamine, and histidine. Cadmium, copper, and inorganic arsenic accumulated in LTS tumors, showing redistribution among intracellular pools, including relocation of copper into the cytochrome c oxidase complex. A gene expression signature based on the LTS metabolic subtype provided prognostic stratification of The Cancer Genome Atlas ccRCC tumors that was independent of genomic alterations.CONCLUSIONThe work identified the TS-related metabolic subtype of ccRCC with vulnerabilities that can be exploited for precision medicine approaches targeting metabolic pathways. The results provided rationale for the development of metabolic biomarkers with diagnostic and prognostic applications using evaluation of OXPHOS status. The metallomic analysis revealed the role of disrupted metal homeostasis in ccRCC, highlighting the importance of studying effects of metals from e-cigarettes and environmental exposures.FUNDINGDepartment of Defense, Veteran Administration, NIH, ACS, and University of Cincinnati Cancer Institute.

Indexed as

Cellular ReprogrammingCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleTobacco SmokingCancerMetabolismOncology

Identifiers

PMID32970633
PMCPMC7773408
OpenAlexW3088756880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.